coumarin has been researched along with Glioblastoma in 2 studies
2H-chromen-2-one: coumarin derivative
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, the aim of our study was to investigate the effect of simple coumarins (osthole, umbelliferone, esculin, and 4-hydroxycoumarin) combined with sorafenib (specific inhibitor of Raf (Rapidly Accelerated Fibrosarcoma) kinase) in programmed death induction in human glioblastoma multiforme (T98G) and anaplastic astrocytoma (MOGGCCM) cells lines." | 3.96 | Antiglioma Potential of Coumarins Combined with Sorafenib. ( Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Rzeski, W; Skalicka-Woźniak, K; Sumorek-Wiadro, J; Zając, A, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sumorek-Wiadro, J | 1 |
| Zając, A | 1 |
| Langner, E | 1 |
| Skalicka-Woźniak, K | 1 |
| Maciejczyk, A | 1 |
| Rzeski, W | 1 |
| Jakubowicz-Gil, J | 1 |
| Gu, G | 1 |
| Xia, H | 1 |
| Hu, Q | 1 |
| Liu, Z | 1 |
| Jiang, M | 1 |
| Kang, T | 1 |
| Miao, D | 1 |
| Tu, Y | 1 |
| Pang, Z | 1 |
| Song, Q | 1 |
| Yao, L | 1 |
| Chen, H | 1 |
| Gao, X | 1 |
| Chen, J | 1 |
2 other studies available for coumarin and Glioblastoma
| Article | Year |
|---|---|
Antiglioma Potential of Coumarins Combined with Sorafenib.
Topics: 4-Hydroxycoumarins; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Beclin-1; Caspase 3; Ce | 2020 |
PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Coumarins; Diagnostic Imaging; Drug Delivery Systems; | 2013 |